Well, we, we can define bronchiectasis as an orphan disease. Orphan because we have a, uh, at the end of the day, a high prevalence disease without any treatment, any approved treatment. Uh, bronchitosis is characterized by inflammation, chronic infection, and lung damage. And in this so-called vicious circle or vicious vortex, these three points interact to lead to a loss of pulmonary function and a loss of quality of life and with a mortality that can be related to bronchiectassis. The prevalence is clearly not well known. We know that since 10 years or 15 years we are starting to work on a registry, the most important registry, the Emberg registry, and this leads us to a better knowledge about the kind of bronchiectasis, the etiology of bronchiectasis, and how bronchiectasis impacts on the patient's life. One of the main points is the understanding of the role of inflammation in this kind of patient. And clearly we uh through the data of the Emberg registry, we reach some interesting information about the pathogenesis of bronchiasis. We know that bronchitis is a very heterogeneous disease because it comes from different etiologies going from postinfectious to. Patients with rheumatoid arthritis or gastrointestinal chronic inflammation, and we know that about 50, from 40 to 50% of them are classified as idiopathic because we can't reach a diagnosis, an ecological diagnosis. In any case, all these patients present inflammation, and inflammation is clearly related also to chronic infection. And we know very well how this can impact on on the disease's natural history. What we address when we look to inflammation is that inflammation is probably mainly related to neutrophil inflammation. And we know that there are some patients, about from 15 to 20% of them with eosinophilic inflammation and some with a mix of the two, but clearly when we look to the problem of inflammation, neutrophil inflammation drives the problem because we know that all the cluster where neutrophil inflammation is the leading cause of inflammation, the patient has more problems, particularly. Exacerbation and we know that the number of exacerbation and the severity of exacerbation are related with the quality of life and mortality. So this is one of the main targets for the future and also for the present, I must say, as we till now we don't have, as I said before, any approved treatment. The first one is the anti-inflammatory drug that works on DPP-1 inhibition that leads to good results in in clinical trials.
Presenter
